rs62053220 genotypes were significantly associated with their corresponding mRNA expression levels in lung cancer tissues in a dominant model (P = 0.048).
effective in patients harboring an EGFR mutation, leaving the remaining 70-90% wildtype EGFR patients with an urgently unmet medical need. The tetraspanin, CD151, is associated with poor prognosis in NSCLC, but the clinical significance of its expression and relationship with EGFR mutation status is unknown. We investigated the association between CD151 expression with EGFR mutation status in NSCLC and determined the prognostic biomarker value of this relationship.
Methods: 157 adenocarcinoma patient lung biopsy sections (from 1989 (from -2011 , were evaluated by immunostaining for CD151 expression and then compared with patient clinicopathological parameters and survival outcome. Gene expression and clinical data from 199 wildtype EGFR patients in the TCGA lung adenocarcinoma (LUAD) cohort were analysed for further validation.
Results: There is a strong association between CD151 expression and wildtype EGFR patients (P = 0.005). CD151 expression was also associated with Chinese ethnicity and TNM (tumor, node and metastasis) stage, respectively. Importantly, higher cumulative incidence of death due to disease was observed in patients with both wildtype EGFR and high CD151 expression when compared against the other subgroups (P = 0.011). In support of this, higher rate of disease-specific death was observed in the high CD151 subgroup from the TCGA LUAD cohort compared to the remaining low CD151 subgroup.
Conclusion:
Expression of both wildtype EGFR and high CD151 is strongly associated with poorer disease outcome compared to other NSCLC subgroups, suggesting that (1) CD151 is a prognostic biomarker which may help to further stratify wildtype EGFR subsets, and (2) CD151 as a therapeutic target in the development of novel alternative and/or complementary agents for the treatment of wildtype EGFR-NSCLC subgroups. EGFR-TKI osimertinib is an effective agent for T790M mutation, the efficacy varies and whether the front line treatment using the 1G or 2G EGFR-TKI affects the efficacy of osimertinib is not wellunderstood. 
QIN YIN
Results: The 14 patients with EG (13.3%) in our group were followed-up 15 months (10-31 months). The median age was 48.5 yearold (38-67 year-old) and 85.7% of them were under the age of 60, meanwhile females had a slightly higher proportion than males (1.8:1). Most patients were at early stage (71.4%) with nonspecific manifestations such as cough, expectoration and lack of rich-lewis phenomenon. EG was often located in tumor or beside the tumor (71.4%), which was all negative in specific stain of pathology. In situ hybridization of EBV-encoded RNA (EBER) was all positive. In our group, there were 2 patients received palliative chemotherapy (the duration of progression-free survival were 8 and 10 months, respectively). Twelve of them underwent surgical resection including 10 with adjuvant or neoadjuvant chemotherapy, of which two had disease relapsed in 8 and 25 months after surgery. None of them had tuberculosis occur, progression or relapse, even if antituberculosis therapy were not taken.
Conclusion: PLELC with EG was lack of specific clinical characteristic compared with the patients without EG. It is important for us to make an exact pathological diagnosis, and attentions should be paid to obtain samples by biopsy and make differential diagnosis. PLELC with EG could receive multimodality therapy such as chemotherapy, and antituberculosis therapy was not necessary. The formation of EG may be caused by immunological hypersensitivity to tumor cell or EBV infection instead of tuberculosis. and Paclitaxel (PTX) was appealing for basic and clinical exploration due to a distinct mechanism of action and non-overlapping toxicities. This study aims to elucidate a potential effect of GEM in combination with PTX.
Methods: To determine half inhibition concentration (IC 50 ), two nonsmall cell lung cancer (NSCLC) cell lines, A549 and H520 were treated with GEM and PTX for 48 h. With a constant ratio of IC 50 , simultaneous exposure of cell lines to drugs by the sequence as follows: GEM!PTX, vice versa PTX!GEM, or GEM and PTX simultaneously (GEM+PTX) to analysis combination Index (CI). Western blot in determining GEM`s effect on acetylation of tubulin Results: IC 50 of GEM in A549 and H520 were 6.6nM and 46.1nM, respectively. IC 50 of PTX in A549 and H520 were 1.35nM and 7.59nM, respectively. The sequence of GEM!PTX in A549 and H520 resulted in slight synergism and strong synergism, respectively. Immunoblotting showed intense expressions band of acetylated tubulin protein in both cell lines in the sequence GEM!PTX.
Conclusion: GEM enhances anti-tumor activity of PTX via modulating tubulin acetylation. GEM!PTX sequence may be a promising candidate regimen against NSCLC. Methods: We conducted a retrospective cohort study using database from the claims database of Taipei Veterans General Hospital, a medical center in Taiwan. New or recurrent stage IIIb and IV NSCLC patients with EGFR mutations receiving more than 3 months as first-line treatment from 2011 to 2016 were enrolled. Primary endpoint was progression-free survival and observation period was 2 years. Secondary endpoint was allcause mortality. Patients using co-medications at least 28 defined daily dose in first three months of TKIs therapy were assigned to comedications groups.
AO047 THE REAL-WORLD EFFICACY OF FIRST-LINE TYROSINE KINASE INHIBITORS IN ASIAN PATIENTS WITH EGFR MUTATION NON-SMALL CELL LUNG CANCER VINCENT YI-FONG SU
Results: A total of 853 subjects (gefitinib: 534, erlotinib: 220, afatinib: 99) were enrolled in the study. The median duration of progression-free survival was 11.5 months in the gefitinib arm, 11.7 months in the erlotinib arm, and 16.1 months in the afatinib arm (log-rank test, P < 0.001). After adjusting for age, sex, EGFR mutation status, lung cancer stage, ECOG performance status, smoking status, radiotherapy, baseline brainmetastases, Charlson Comorbidity Index, co-medications, afatinib showed lower progression risk compared with gefitinib (hazard ratio
[HR] = 0.54, 95%CI = 0.41-0.71) and erlotinib (HR = 0.62, 95% CI = 0.46-0.83). HR of progression for TKI users received systemic steroids were higher than TKI alone users (HR = 1.47, 95% CI = 1.08-2.01). Overall survival was significantly longer in the patients who received afatinib or erlotinib compared to those who received gefitinib. In the section of brain metastases, there was no significant difference among three TKIs.
